Fulcrum Therapeutics, Inc. Common Stock (FULC) Stock
NASDAQ · FULC
Key stats
- Market cap
- $285.67M
- Price / Earnings ratio
- -3.3x
- EPS (TTM)
- -$1.21
- Volume
- Loading
- 52-week high
- $15.74
- 52-week low
- $2.83
Source: third-party data provider, as of November 13, 2026
Compare with FULC
Recent news

Business Wire
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
NeutralFULCSeptember 5, 2026
Business WireNeutral
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
FULC

Business Wire
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
FULCAugust 19, 2026
Business Wire
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
FULC

MarketBeat
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
FULCAugust 17, 2026
MarketBeat
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
FULC

Business Wire
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
FULCAugust 17, 2026
Business Wire
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
FULC
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 52.45
- MACD 12/26/9
- -0.00
- EMA 9 of MACD
- -0.01
- MACD histogram
- 0.01
- SMA 50
- $3.74
- Price above SMA 50
- EMA 50
- $3.76
- Price below EMA 50
- SMA 200
- $5.59
- Price below SMA 200
- EMA 200
- $5.95
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
96M63M32M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
440M290M145M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-74.9M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Business Wire
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
NeutralFULCSeptember 5, 2026
Business WireNeutral
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
FULC

Business Wire
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
FULCAugust 19, 2026
Business Wire
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
FULC

MarketBeat
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
FULCAugust 17, 2026
MarketBeat
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
FULC

Business Wire
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
FULCAugust 17, 2026
Business Wire
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
FULC

Reuters
Fulcrum to merge with Slate in all-stock deal after drug setback
FULCAugust 17, 2026
Reuters
Fulcrum to merge with Slate in all-stock deal after drug setback
FULC

Zacks Investment Research
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
FULCJune 5, 2026
Zacks Investment Research
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
FULC

Business Wire
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud
FULCJune 4, 2026
Business Wire
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud
FULC

Zacks Investment Research
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
FULCJune 3, 2026
Zacks Investment Research
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
FULC

Stocktwits
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
FULCJune 3, 2026
Stocktwits
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
FULC

Reuters
Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns
FULCJune 2, 2026
Reuters
Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns
FULC
News tone: automated (AI) classification of the article's content, not a price prediction.
About Fulcrum Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees9
CEOMr. Alexander C. Sapir
IPO DateJul 18, 2019
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Alexander C. Sapir | CEO, President & Director | 1967 |
| Mr. Alan A. Musso C.M.A., CPA | CFO, Treasurer & Principal Accounting Officer | 1962 |
| Mr. Curtis G. Oltmans J.D. | Chief Legal Officer, Head of External Affairs & Corporate Secretary | 1963 |
| Dr. Bradley E. Bernstein M.D., Ph.D. | Founder | — |
| Dr. Michael R. Green | Founder | — |
| Dr. Rudolf Jaenisch M.D., Ph.D. | Founder | — |
| Dr. Tsun-Huei Lee M.D., Ph.D. | Founder | 1964 |
| Dr. Danny Reinberg | Founder | — |
| Dr. Iain Fraser DPHIL | Senior Vice President of Early Development | — |
| Bobby Riehle Ph.D. | Head of Program Strategy & Vice President | — |
Fundamentals
Valuation
Price-to-sales ratio3.55
Price-to-book value0.91
Profitability
Return on Equity-29.00%
Return on Assets-27.00%
EBITDA$-83.75M
Trading
Average volume1,315,385
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 52.45
- MACD 12/26/9
- -0.00
- EMA 9 of MACD
- -0.01
- MACD histogram
- 0.01
- SMA 50
- $3.74
- Price above SMA 50
- EMA 50
- $3.76
- Price below EMA 50
- SMA 200
- $5.59
- Price below SMA 200
- EMA 200
- $5.95
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -18.8 | +26.4 | ||||||||||
| 2022 | -31.8 | -9.8 | +112.3 | -59.5 | -27.3 | -29.2 | +19.5 | +31.7 | -1.2 | -31.9 | +18.1 | +8.7 |
| 2023 | +59.6 | -52.1 | -54.7 | -9.7 | +0.0 | +14.2 | +17.5 | +49.1 | -22.4 | -11.0 | +28.0 | +35.3 |
| 2024 | +0.1 | +27.3 | -14.1 | -23.4 | +7.1 | -24.2 | +47.1 | -5.1 | -55.9 | -12.2 | +19.9 | +21.1 |
| 2025 | -18.2 | -5.8 | -11.1 | +39.5 | +57.1 | -1.1 | -1.6 | -5.1 | +43.5 | -6.2 | +21.3 | +14.6 |
| 2026 | -1.7 | -21.8 | -1.8 | -4.7 | -6.0 | -43.0 | -1.6 | +4.9 | -4.4 | +0.8 | +1.9 |
Compare stocks
Market cap
$285.67M
-
-
-
Price / Earnings ratio
-3.30
-
-
-
Price / Sales ratio
3.55
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,315,385
-
-
-
Earnings per share
$-1.21
-
-
-



